Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of Managed Care & Specialty Pharmacy|October 29, 2021
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United StatesAnuja Chatterjee, Sheila Shapouri, Beenish S Manzoor, et al.
Pharmacoeconomics - Open|November 5, 2022
A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in CanadaAnuja Chatterjee, Gijs van de Wetering, Ron Goeree, et al.
Journal of Medical Economics|June 11, 2021
Cost-effectiveness analysis of anti-IL-5 therapies of severe eosinophilic asthma in SpainFrancisco Javier González-Barcala, Xavier Muñoz-Gall, Esther Mariscal, et al.
Pharmacoeconomics - Open|November 7, 2025
Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility AnalysisGijs van de Wetering, Carolyn Owen, Versha Banerji, et al.
Advances in Therapy|June 17, 2025
Long-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation ModelAdnan Alsumali, Vallerie McLaughlin, Jestinah Chevure, et al.
Journal of Medical Economics|August 26, 2023
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspectiveNishit Dhanji, Tassia Cristina Decimoni, Matthew T D Dyer, et al.
BMC Family Practice|December 11, 2012
The CareWell-primary care program: design of a cluster controlled trial and process evaluation of a complex intervention targeting community-dwelling frail elderlyFranca G H Ruikes, Antoinette R M Meys, Gijs van de Wetering, et al.
Journal of Medical Economics|June 8, 2026
A global model for symptomatic obstructive hypertrophic cardiomyopathy to assess the cost-effectiveness of mavacamten: results from a Dutch societal perspectiveVarun Ektare, Claire Simons, Kasper Johannesen, et al.
Pageof 2